Status:
COMPLETED
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Nonvalvular Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrilla...
Eligibility Criteria
Inclusion
- Be oral anticoagulant naive during the 365 days before the day of the first qualifying oral anticoagulant (rivaroxaban or VKA) dispensing, and
- Have ≥365 days of continuous medical and prescription coverage before initiation of oral anticoagulation (which serves as the study's baseline period)
Exclusion
- \<18 years of age
- \<2 International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification diagnosis codes for atrial fibrillation
- Valvular heart disease
- Transient cause of NVAF
- Venous thromboembolism
- Hip or knee arthroplasty
- Malignant cancer
- Pregnancy
- \>1 oral anticoagulant prescribed (on index date)
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2019
Estimated Enrollment :
78517 Patients enrolled
Trial Details
Trial ID
NCT03374540
Start Date
December 1 2017
End Date
August 30 2019
Last Update
August 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases
Multiple Locations, Washington, United States, 20001